1
|
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
|
Lancet
|
2002
|
16.56
|
2
|
Class of antiretroviral drugs and the risk of myocardial infarction.
|
N Engl J Med
|
2007
|
12.93
|
3
|
Combination antiretroviral therapy and the risk of myocardial infarction.
|
N Engl J Med
|
2003
|
12.23
|
4
|
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
|
JAMA
|
2008
|
11.72
|
5
|
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
|
JAMA
|
2010
|
9.26
|
6
|
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
|
Arch Intern Med
|
2006
|
9.21
|
7
|
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.
|
JAMA
|
2012
|
8.94
|
8
|
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
|
Lancet
|
2008
|
8.73
|
9
|
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.
|
Lancet Infect Dis
|
2008
|
5.94
|
10
|
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
|
AIDS
|
2003
|
5.61
|
11
|
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
|
Clin Infect Dis
|
2005
|
5.20
|
12
|
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
|
AIDS
|
2007
|
4.31
|
13
|
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
|
Diabetes Care
|
2008
|
4.10
|
14
|
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
|
Lancet
|
2004
|
3.59
|
15
|
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.
|
AIDS
|
2010
|
3.47
|
16
|
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
|
J Infect Dis
|
2010
|
3.30
|
17
|
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
|
J Acquir Immune Defic Syndr
|
2007
|
3.18
|
18
|
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
|
J Infect Dis
|
2013
|
3.04
|
19
|
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.
|
AIDS
|
2010
|
2.98
|
20
|
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
|
AIDS
|
2010
|
2.85
|
21
|
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.
|
J Acquir Immune Defic Syndr
|
2014
|
2.79
|
22
|
Mortality and progression to AIDS after starting highly active antiretroviral therapy.
|
AIDS
|
2003
|
2.78
|
23
|
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
2.70
|
24
|
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
|
J Acquir Immune Defic Syndr
|
2010
|
2.59
|
25
|
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.
|
Clin Infect Dis
|
2007
|
2.51
|
26
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
27
|
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
|
J Hepatol
|
2005
|
2.45
|
28
|
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
|
AIDS
|
2008
|
2.27
|
29
|
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
|
AIDS
|
2013
|
2.11
|
30
|
Chronic renal failure among HIV-1-infected patients.
|
AIDS
|
2007
|
2.07
|
31
|
Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).
|
Circulation
|
2009
|
2.01
|
32
|
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
|
Arch Intern Med
|
2005
|
1.97
|
33
|
Continuous antiretroviral therapy decreases bone mineral density.
|
AIDS
|
2009
|
1.96
|
34
|
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
|
AIDS
|
2009
|
1.90
|
35
|
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
|
PLoS Med
|
2004
|
1.89
|
36
|
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
|
Clin Infect Dis
|
2009
|
1.86
|
37
|
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.
|
Antivir Ther
|
2008
|
1.83
|
38
|
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.75
|
39
|
HIV-1 infection and cognitive impairment in the cART era: a review.
|
AIDS
|
2011
|
1.72
|
40
|
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
|
Ann Intern Med
|
2002
|
1.70
|
41
|
Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis.
|
BMC Med
|
2014
|
1.69
|
42
|
An internationally generalizable risk index for mortality after one year of antiretroviral therapy.
|
AIDS
|
2013
|
1.64
|
43
|
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
|
Clin Pharmacol Ther
|
2002
|
1.61
|
44
|
The restoration potential of the Mesopotamian marshes of Iraq.
|
Science
|
2005
|
1.60
|
45
|
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.
|
Epidemiology
|
2011
|
1.59
|
46
|
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study.
|
Clin Infect Dis
|
2014
|
1.59
|
47
|
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2011
|
1.58
|
48
|
Factors affecting transmission of mucosal human papillomavirus.
|
Lancet Infect Dis
|
2010
|
1.56
|
49
|
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
|
Clin Infect Dis
|
2010
|
1.54
|
50
|
Effects of antiretroviral therapy on semen quality.
|
AIDS
|
2008
|
1.54
|
51
|
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
|
PLoS Med
|
2012
|
1.54
|
52
|
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
|
AIDS
|
2005
|
1.52
|
53
|
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
|
AIDS
|
2006
|
1.52
|
54
|
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.
|
AIDS
|
2015
|
1.44
|
55
|
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
|
AIDS
|
2003
|
1.43
|
56
|
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
|
AIDS
|
2003
|
1.41
|
57
|
One-pot synthesis of highly luminescent InP/ZnS nanocrystals without precursor injection.
|
J Am Chem Soc
|
2008
|
1.39
|
58
|
Virological rebound after suppression on highly active antiretroviral therapy.
|
AIDS
|
2003
|
1.34
|
59
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
|
Euro Surveill
|
2015
|
1.29
|
60
|
Prospects of nanoscience with nanocrystals.
|
ACS Nano
|
2015
|
1.27
|
61
|
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
|
AIDS
|
2009
|
1.27
|
62
|
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
|
Clin Infect Dis
|
2014
|
1.25
|
63
|
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.
|
Circulation
|
2008
|
1.24
|
64
|
Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy.
|
Clin Infect Dis
|
2011
|
1.22
|
65
|
Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy.
|
J Infect Dis
|
2009
|
1.20
|
66
|
Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
1.19
|
67
|
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
|
AIDS
|
2008
|
1.18
|
68
|
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
|
AIDS
|
2012
|
1.16
|
69
|
High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.
|
PLoS One
|
2013
|
1.16
|
70
|
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
|
AIDS
|
2002
|
1.15
|
71
|
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
|
AIDS
|
2007
|
1.15
|
72
|
Predictors of hypertension and changes of blood pressure in HIV-infected patients.
|
Antivir Ther
|
2005
|
1.14
|
73
|
Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda.
|
Pediatr Infect Dis J
|
2014
|
1.12
|
74
|
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
|
Arch Intern Med
|
2010
|
1.12
|
75
|
Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy.
|
J Acquir Immune Defic Syndr
|
2009
|
1.11
|
76
|
Triple HIV-1 infection.
|
N Engl J Med
|
2005
|
1.09
|
77
|
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
|
AIDS
|
2002
|
1.07
|
78
|
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.
|
AIDS
|
2010
|
1.07
|
79
|
Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study.
|
PLoS One
|
2013
|
1.06
|
80
|
Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
|
J Infect Dis
|
2005
|
1.06
|
81
|
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
82
|
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.04
|
83
|
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
|
AIDS
|
2014
|
1.03
|
84
|
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
|
Antivir Ther
|
2005
|
1.03
|
85
|
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
|
J Int AIDS Soc
|
2012
|
1.03
|
86
|
High prevalence of reduced bone mineral density in primary HIV-1-infected men.
|
AIDS
|
2010
|
1.02
|
87
|
Effect of poly(ethylene glycol) length on the in vivo behavior of coated quantum dots.
|
Langmuir
|
2009
|
1.01
|
88
|
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
|
Clin Nephrol
|
2012
|
1.00
|
89
|
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.
|
Antivir Ther
|
2010
|
1.00
|
90
|
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
|
AIDS
|
2003
|
0.99
|
91
|
Lipid profiles associated with antiretroviral drug choices.
|
Curr Opin Infect Dis
|
2003
|
0.99
|
92
|
Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
|
Antivir Ther
|
2004
|
0.99
|
93
|
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
|
BMC Infect Dis
|
2013
|
0.98
|
94
|
HIV-1 sequence evolution in vivo after superinfection with three viral strains.
|
Retrovirology
|
2007
|
0.98
|
95
|
Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.
|
Atherosclerosis
|
2008
|
0.98
|
96
|
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.
|
Clin Infect Dis
|
2012
|
0.98
|
97
|
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
|
AIDS
|
2013
|
0.98
|
98
|
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
|
Clin Infect Dis
|
2008
|
0.98
|
99
|
Chelating ligands for nanocrystals' surface functionalization.
|
J Am Chem Soc
|
2004
|
0.97
|
100
|
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.
|
J Clin Virol
|
2003
|
0.96
|
101
|
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
|
AIDS
|
2004
|
0.96
|
102
|
Impact of nevirapine on lipid metabolism.
|
J Acquir Immune Defic Syndr
|
2003
|
0.96
|
103
|
Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection.
|
AIDS
|
2015
|
0.96
|
104
|
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
|
AIDS
|
2011
|
0.96
|
105
|
Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2012
|
0.96
|
106
|
HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls.
|
AIDS
|
2016
|
0.95
|
107
|
Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection.
|
J Immunol
|
2006
|
0.94
|
108
|
Associations between immune depression and cardiovascular events in HIV infection.
|
AIDS
|
2013
|
0.94
|
109
|
Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.
|
Diabetes Care
|
2008
|
0.94
|
110
|
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
|
Antivir Ther
|
2007
|
0.93
|
111
|
Unraveling the core-shell structure of ligand-capped Sn/SnOx nanoparticles by surface-enhanced nuclear magnetic resonance, Mössbauer, and X-ray absorption spectroscopies.
|
ACS Nano
|
2014
|
0.93
|
112
|
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
|
J Antimicrob Chemother
|
2003
|
0.93
|
113
|
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
|
Arterioscler Thromb Vasc Biol
|
2009
|
0.92
|
114
|
Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach.
|
AIDS Care
|
2013
|
0.92
|
115
|
Prediction of residual time to AIDS and death based on markers and cofactors.
|
J Acquir Immune Defic Syndr
|
2003
|
0.92
|
116
|
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.
|
AIDS
|
2011
|
0.91
|
117
|
Abacavir and cardiovascular risk.
|
Curr Opin Infect Dis
|
2010
|
0.91
|
118
|
Infection with HIV-1 induces a decrease in mtDNA.
|
J Infect Dis
|
2005
|
0.91
|
119
|
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
|
J Hepatol
|
2013
|
0.90
|
120
|
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
|
J Clin Endocrinol Metab
|
2013
|
0.90
|
121
|
Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.
|
Pediatr Infect Dis J
|
2013
|
0.90
|
122
|
Internal structure of InP/ZnS nanocrystals unraveled by high-resolution soft X-ray photoelectron spectroscopy.
|
ACS Nano
|
2010
|
0.89
|
123
|
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.
|
AIDS
|
2011
|
0.89
|
124
|
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
|
J Acquir Immune Defic Syndr
|
2008
|
0.89
|
125
|
The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.
|
AIDS
|
2010
|
0.89
|
126
|
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
|
Antivir Ther
|
2004
|
0.89
|
127
|
Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection.
|
Antivir Ther
|
2012
|
0.88
|
128
|
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
|
Ther Drug Monit
|
2007
|
0.88
|
129
|
Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure.
|
J Clin Endocrinol Metab
|
2002
|
0.87
|
130
|
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
|
PLoS One
|
2009
|
0.87
|
131
|
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.
|
AIDS
|
2004
|
0.86
|
132
|
Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.86
|
133
|
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
|
J Acquir Immune Defic Syndr
|
2015
|
0.86
|
134
|
Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy.
|
AIDS
|
2016
|
0.85
|
135
|
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
|
Expert Opin Drug Saf
|
2005
|
0.85
|
136
|
Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
|
Antivir Ther
|
2010
|
0.85
|
137
|
Low bone mineral density, regardless of HIV status, in men who have sex with men.
|
J Infect Dis
|
2012
|
0.85
|
138
|
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
|
Clin Infect Dis
|
2013
|
0.85
|
139
|
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
|
J Infect Dis
|
2005
|
0.85
|
140
|
Amine-induced growth of an In2O3 shell on colloidal InP nanocrystals.
|
Chem Commun (Camb)
|
2007
|
0.85
|
141
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
|
AIDS
|
2012
|
0.85
|
142
|
How bad is HAART for the HEART?
|
AIDS
|
2003
|
0.84
|
143
|
Highly luminescent Cd1-xZnxSe/ZnS core/shell nanocrystals emitting in the blue-green spectral range.
|
Small
|
2007
|
0.84
|
144
|
Viral replication under combination antiretroviral therapy: a comparison of four different regimens.
|
J Acquir Immune Defic Syndr
|
2002
|
0.84
|
145
|
Semen quality remains stable during 96 weeks of untreated human immunodeficiency virus-1 infection.
|
Fertil Steril
|
2007
|
0.84
|
146
|
Effect of surface ligands on the optical properties of aqueous soluble CdTe quantum dots.
|
Nanoscale Res Lett
|
2012
|
0.83
|
147
|
Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury.
|
J Neurochem
|
2002
|
0.83
|
148
|
Europium doped In(Zn)P/ZnS colloidal quantum dots.
|
Dalton Trans
|
2013
|
0.83
|
149
|
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
|
Antivir Ther
|
2009
|
0.83
|
150
|
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
|
J Infect Dis
|
2006
|
0.83
|
151
|
Cell-permeable Ln(III) chelate-functionalized InP quantum dots as multimodal imaging agents.
|
ACS Nano
|
2011
|
0.83
|
152
|
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
|
Clin Infect Dis
|
2015
|
0.83
|
153
|
Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands.
|
Antivir Ther
|
2010
|
0.82
|
154
|
Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons.
|
AIDS
|
2016
|
0.82
|
155
|
Aqueous phase transfer of InP/ZnS nanocrystals conserving fluorescence and high colloidal stability.
|
ACS Nano
|
2011
|
0.82
|
156
|
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
|
Antivir Ther
|
2005
|
0.82
|
157
|
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
|
J Virol
|
2005
|
0.82
|
158
|
Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2010
|
0.82
|
159
|
White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment.
|
AIDS
|
2016
|
0.82
|
160
|
Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine.
|
AIDS
|
2016
|
0.82
|
161
|
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.
|
J Antimicrob Chemother
|
2013
|
0.81
|
162
|
A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
|
Am J Physiol Endocrinol Metab
|
2009
|
0.81
|
163
|
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
|
Antivir Ther
|
2007
|
0.81
|
164
|
Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation.
|
J Infect Dis
|
2007
|
0.81
|
165
|
Drug interactions between statins and antiretroviral agents.
|
Curr Opin HIV AIDS
|
2008
|
0.81
|
166
|
Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis.
|
Antivir Ther
|
2011
|
0.81
|
167
|
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
|
Antivir Ther
|
2012
|
0.81
|
168
|
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.
|
AIDS Rev
|
2010
|
0.80
|
169
|
Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!
|
Curr Opin HIV AIDS
|
2007
|
0.80
|
170
|
Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy.
|
Clin Infect Dis
|
2012
|
0.80
|
171
|
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
|
J Antimicrob Chemother
|
2006
|
0.80
|
172
|
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
|
Antivir Ther
|
2009
|
0.80
|
173
|
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
|
J Infect Dis
|
2007
|
0.80
|
174
|
Size and ligand effects on the electrochemical and spectroelectrochemical responses of CdSe nanocrystals.
|
Phys Chem Chem Phys
|
2005
|
0.80
|
175
|
Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort.
|
Arch Intern Med
|
2002
|
0.80
|
176
|
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.
|
Clin Infect Dis
|
2016
|
0.79
|
177
|
Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study.
|
Antivir Ther
|
2011
|
0.79
|
178
|
The long-term consequences of antiretroviral therapy: a review.
|
J HIV Ther
|
2006
|
0.79
|
179
|
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study.
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
180
|
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
|
Antivir Ther
|
2003
|
0.79
|
181
|
Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children.
|
Medicine (Baltimore)
|
2016
|
0.79
|
182
|
The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
|
Antivir Ther
|
2011
|
0.79
|
183
|
Dialysis and renal transplantation in HIV-infected patients: a European survey.
|
J Acquir Immune Defic Syndr
|
2010
|
0.79
|
184
|
CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time.
|
AIDS
|
2015
|
0.78
|
185
|
Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.
|
Atherosclerosis
|
2009
|
0.78
|
186
|
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
|
Antivir Ther
|
2006
|
0.78
|
187
|
Compact quantum dot-antibody conjugates for FRET immunoassays with subnanomolar detection limits.
|
Nanoscale
|
2016
|
0.78
|
188
|
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
|
AIDS
|
2012
|
0.78
|
189
|
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
|
J Acquir Immune Defic Syndr
|
2016
|
0.78
|
190
|
Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals.
|
AIDS
|
2017
|
0.77
|
191
|
Synthesis of homogeneous FePt nanoparticles using a nitrile ligand.
|
Small
|
2008
|
0.77
|
192
|
Sympathetic nervous system function in HIV-associated adipose redistribution syndrome.
|
AIDS
|
2006
|
0.77
|
193
|
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.
|
BMC Nephrol
|
2014
|
0.77
|
194
|
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
|
Expert Opin Drug Saf
|
2015
|
0.77
|
195
|
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
|
Scand J Infect Dis
|
2008
|
0.77
|
196
|
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.
|
J Clin Endocrinol Metab
|
2004
|
0.77
|
197
|
Influence of the catalyst type on the growth of carbon nanotubes via methane chemical vapor deposition.
|
J Phys Chem B
|
2006
|
0.77
|
198
|
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
|
J Infect Dis
|
2007
|
0.77
|
199
|
Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
|
HIV Clin Trials
|
2007
|
0.77
|
200
|
Surface oxidation of tin chalcogenide nanocrystals revealed by 119Sn-Mössbauer spectroscopy.
|
J Am Chem Soc
|
2012
|
0.77
|
201
|
White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy.
|
AIDS
|
2016
|
0.77
|
202
|
Luminescence of polyethylene glycol coated CdSeTe/ZnS and InP/ZnS nanoparticles in the presence of copper cations.
|
Chemphyschem
|
2011
|
0.77
|
203
|
A simple and general route for monofunctionalization of fluorescent and magnetic nanoparticles using peptides.
|
Nanotechnology
|
2011
|
0.77
|
204
|
Quenching dynamics in CdSe nanoparticles: surface-induced defects upon dilution.
|
ACS Nano
|
2012
|
0.77
|
205
|
Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced Immunodeficiency.
|
J Acquir Immune Defic Syndr
|
2016
|
0.77
|
206
|
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
|
AIDS
|
2004
|
0.76
|
207
|
When to Start Antiretroviral Therapy and What to Start With-- A European Perspective.
|
Curr Infect Dis Rep
|
2003
|
0.76
|
208
|
Higher subcortical and white matter cerebral blood flow in perinatally HIV-infected children.
|
Medicine (Baltimore)
|
2017
|
0.75
|
209
|
The art of managing human immunodeficiency virus infection: a balancing act.
|
Clin Infect Dis
|
2009
|
0.75
|
210
|
HIV and ageing: improving quantity and quality of life.
|
Curr Opin HIV AIDS
|
2016
|
0.75
|
211
|
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.
|
Medicine (Baltimore)
|
2016
|
0.75
|
212
|
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?
|
AIDS
|
2016
|
0.75
|
213
|
Rational design of the gram-scale synthesis of nearly monodisperse semiconductor nanocrystals.
|
Nanoscale Res Lett
|
2011
|
0.75
|
214
|
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.
|
AIDS
|
2016
|
0.75
|
215
|
Synthesis and surface chemistry of high quality wurtzite and kesterite Cu2ZnSnS4 nanocrystals using tin(II) 2-ethylhexanoate as a new tin source.
|
Chem Commun (Camb)
|
2015
|
0.75
|
216
|
Layer-by-layer assembled composite films of side-functionalized poly(3-hexylthiophene) and CdSe nanocrystals: electrochemical, spectroelectrochemical and photovoltaic properties.
|
Phys Chem Chem Phys
|
2008
|
0.75
|
217
|
Impact of HIV care facility characteristics on the cascade of care in HIV-infected patients in the Netherlands.
|
AIDS
|
2016
|
0.75
|
218
|
Optimizing the relaxivity of GdIII complexes appended to InP/ZnS quantum dots by linker tuning.
|
Dalton Trans
|
2013
|
0.75
|
219
|
Mitochondria, HIV infection and its treatment: where do we go from here?
|
Antivir Ther
|
2005
|
0.75
|
220
|
Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange.
|
Antivir Ther
|
2015
|
0.75
|
221
|
High need to switch cART or co-medication with the initiation of DAAs in elderly HIV/HCV co-infected patients.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
222
|
Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.
|
PLoS Biol
|
2017
|
0.75
|
223
|
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals.
|
AIDS
|
2016
|
0.75
|
224
|
Epidemiology of ageing with HIV: what can we learn from cohorts?
|
AIDS
|
2017
|
0.75
|
225
|
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
226
|
Editorial comment.
|
Curr Opin HIV AIDS
|
2007
|
0.75
|
227
|
Working together to provide generics for health.
|
Antivir Ther
|
2014
|
0.75
|
228
|
Aqueous synthesis of DNA-Functionalized Near-Infrared AgInS2/ZnS Core/Shell Quantum Dots.
|
ACS Appl Mater Interfaces
|
2020
|
0.75
|
229
|
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
230
|
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
231
|
Cerebral blood flow and cognitive function in HIV-infected men with sustained suppressed viremia on combination antiretroviral therapy.
|
AIDS
|
2017
|
0.75
|
232
|
Langmuir-Schaeffer monolayers of colloidal nanocrystals for cost-efficient quantum dot light-emitting diodes.
|
Adv Mater
|
2012
|
0.75
|
233
|
Hypertension in people living with HIV.
|
Curr Opin HIV AIDS
|
2017
|
0.75
|
234
|
Stable colloidal solutions of high-temperature-annealed L10 FePt nanoparticles.
|
Small
|
2010
|
0.75
|
235
|
Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|